Literature DB >> 25788694

A chemical genetics approach for the functional assessment of novel cancer genes.

Qianhe Zhou1, Adnan Derti2, David Ruddy2, Daniel Rakiec2, Iris Kao2, Michelle Lira1, Veronica Gibaja1, HoMan Chan1, Yi Yang3, Junxia Min1, Michael R Schlabach1, Frank Stegmeier4.   

Abstract

Assessing the functional significance of novel putative oncogenes remains a significant challenge given the limitations of current loss-of-function tools. Here, we describe a method that employs TALEN or CRISPR/Cas9-mediated knock-in of inducible degron tags (Degron-KI) that provides a versatile approach for the functional characterization of novel cancer genes and addresses many of the shortcomings of current tools. The Degron-KI system allows for highly specific, inducible, and allele-targeted inhibition of endogenous protein function, and the ability to titrate protein depletion with this system is able to better mimic pharmacologic inhibition compared with RNAi or genetic knockout approaches. The Degron-KI system was able to faithfully recapitulate the effects of pharmacologic EZH2 and PI3Kα inhibitors in cancer cell lines. The application of this system to the study of a poorly understood putative oncogene, SF3B1, provided the first causal link between SF3B1 hotspot mutations and splicing alterations. Surprisingly, we found that SF3B1-mutant cells are not dependent upon the mutated allele for in vitro growth, but instead depend upon the function of the remaining wild-type alleles. Collectively, these results demonstrate the broad utility of the Degron-KI system for the functional characterization of cancer genes. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25788694     DOI: 10.1158/0008-5472.CAN-14-2930

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Authors:  Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor
Journal:  Cancer Cell       Date:  2018-11-01       Impact factor: 31.743

Review 2.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

Review 3.  Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.

Authors:  Jermaine L Jenkins; Clara L Kielkopf
Journal:  Trends Genet       Date:  2017-03-31       Impact factor: 11.639

Review 4.  Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Authors:  Diego M Marzese; Ayla O Manughian-Peter; Javier I J Orozco; Dave S B Hoon
Journal:  Clin Exp Metastasis       Date:  2018-05-29       Impact factor: 5.150

Review 5.  How do messenger RNA splicing alterations drive myelodysplasia?

Authors:  Poorval Joshi; Stephanie Halene; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-03-27       Impact factor: 22.113

6.  A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Authors:  Sabrina Bondu; Anne-Sophie Alary; Carine Lefèvre; Alexandre Houy; Grace Jung; Thibaud Lefebvre; David Rombaut; Ismael Boussaid; Abderrahmane Bousta; François Guillonneau; Prunelle Perrier; Samar Alsafadi; Michel Wassef; Raphaël Margueron; Alice Rousseau; Nathalie Droin; Nicolas Cagnard; Sophie Kaltenbach; Susann Winter; Anne-Sophie Kubasch; Didier Bouscary; Valeria Santini; Andrea Toma; Mathilde Hunault; Aspasia Stamatoullas; Emmanuel Gyan; Thomas Cluzeau; Uwe Platzbecker; Lionel Adès; Hervé Puy; Marc-Henri Stern; Zoubida Karim; Patrick Mayeux; Elizabeta Nemeth; Sophie Park; Tomas Ganz; Léon Kautz; Olivier Kosmider; Michaëla Fontenay
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

7.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Authors:  Liang Chen; Jia-Yu Chen; Yi-Jou Huang; Ying Gu; Jinsong Qiu; Hao Qian; Changwei Shao; Xuan Zhang; Jing Hu; Hairi Li; Shunmin He; Yu Zhou; Omar Abdel-Wahab; Dong-Er Zhang; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2018-01-27       Impact factor: 17.970

8.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 9.  CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.

Authors:  M Sachdeva; N Sachdeva; M Pal; N Gupta; I A Khan; M Majumdar; A Tiwari
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

10.  A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Authors:  Nikhil Wagle; Rachel A Freedman; Sara M Balch; Ines Vaz-Luis; Tianyu Li; Nabihah Tayob; Esha Jain; Karla Helvie; Jorge E Buendia-Buendia; Erin Shannon; Steven J Isakoff; Nadine M Tung; Ian E Krop; Nancy U Lin
Journal:  Breast Cancer Res Treat       Date:  2021-07-24       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.